Allianz Research Institute

Eli Lilly monoclonal antibody cocktail has preliminary results show that patients positive with covid19 with risk factors such as Age obesity Diabetes Hypertension and cardiovascular disease Have reduce hospitalization as seen below. ... Lilly has decided to increase the numbers enrolled form 250 to 500 individuals Additionally added 12-18 years of age with underlying neurological issues or respiratory disease such as asthma. If you have tested positive for covid19 within 72 hours. Please contact us. Additionally if you know people that have tested positive we can prophylaxis you with the AstraZeneca monoclonal antibody cocktail as well.

One of many reasons for overall decreasing death rates due to SARS -CoV2: just less people at risk. A large majority of elderly, diabetic, cardiac, hypertensiv...e obese patients have died. The average age of hospitalized COVID-19 patients also dropped from 63 to 47. In March, while 73 percent had chronic conditions like lung disease and diabetes, by mid-June only about 65 percent had such risk factors. Journal of Hospital Medicine from NYU.

FDA approves remdesvir for treatment of covid19

We are excited to be involved in both treatment as well as prophylaxis clinical trials using monoclonal antibodies against covid19. These federally funded research hopes to bridge the gap until an effective vaccine again covid19. To find out more please contact us through IM. Or email us at [email protected] Or IM us on Facebook.

It is an honor to be able to participate in these types of clinical trials. To find out more please contact us.

Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Improved oxygenation was observed in Baricitinib arm.

Regeneron antibody cocktail reduce hospitalization from 15% to 4% From a previous post, Lilly’s antibody cocktail reduce hospitalization from 15% to 0%. We are currently contributing our research in this area. To find out more please contact me directly.

Covid-19 Have you been diagnosed with covid19 within the last 48-72 hours. Monoclonal antibodies cocktail was given to our president which likely allowed him to be discharged from the hospital. ... We are conducted a clinical trial with a cocktail of monoclonal antibodies. Data thus far are described below. The rate of COVID-related hospitalization and ER visits was lower for patients treated with combination therapy (0.9 percent) versus placebo (5.8 percent), a relative risk reduction of 84.5 percent (p=0.049). This was also similar to observations for LY-CoV555 monotherapy. If interested please contact us. https://finance.yahoo.com//lilly-provides-comprehensive-pr

From England and oxford university Hydrochloroquine once promoted by Donald Trump does absolutely nothing. Even our president once stickened with covid was not given the drug he had advocated. The last shove of dirt on HCQ coffin.

From U Penn HCQ does not work

Live and love science. We report that at least 101 of 987 patients with life-threatening COVID-19 pneumonia had neutralizing IgG auto-Abs against IFN- (13 patients), the 13 types of IFN- (36), or both (52), at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1,227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 were men. A B cell auto-immune phenocopy of inborn errors of type I IFN immunity underlies life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.